Skip to main content

Advertisement

Log in

An adeno-associated virus vector penetrates the blood–brain barrier in non-human primates

  • Research Briefing
  • Published:

From Nature Biomedical Engineering

View current issue Submit your manuscript

Developing gene therapy for use in the central nervous system has been hampered by the lack of an efficient vector for gene delivery. We report an adeno-associated virus vector with an enhanced ability to cross the blood–brain barrier in both rodents and non-human primates, and use it to develop systemic anti-tumour gene therapies for glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Engineering AAV capsids that penetrate the BBB.

References

  1. Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017). An article that presents the first clinical success of AAV9-mediated gene therapy.

    Article  CAS  PubMed  Google Scholar 

  2. Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839–862 (2019). A review article that presents the progress and challenges of CNS gene delivery using AAV.

    Article  CAS  PubMed  Google Scholar 

  3. Gray, S. J. The evolution of adeno-associated virus capsids for CNS gene therapy. Cell Gene Ther. Insights 5, 1361–1368 (2019). A review article that presents the limitations of current AAV capsids for CNS application.

    Article  Google Scholar 

  4. Sarkaria, J. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro. Oncol. 20, 184–191 (2018). This review article presents emerging clinical evidence of the critical role of the BBB in glioblastoma treatment.

    Article  CAS  PubMed  Google Scholar 

  5. Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106–115 (2021). Using a directed revolution screening method, this article identifies AAV capsids that penetrate the BBB in mice and marmosets.

    Article  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-022-00938-7 (2022).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

An adeno-associated virus vector penetrates the blood–brain barrier in non-human primates. Nat. Biomed. Eng 6, 1201–1202 (2022). https://doi.org/10.1038/s41551-022-00939-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-022-00939-6

  • Springer Nature Limited

Navigation